NewCo News: CDG's p28 Shines in Phase I; ASCO Debut a 'Turning Point'
By Jennifer Boggs
Thursday, July 7, 2011
Amid the flood of data reported at last month's American Society of Clinical Oncology (ASCO) meeting, small biotech CDG Therapeutics Inc. emerged from a decade of stealth with the first clinical data for its p28 peptide program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.